Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy

被引：0
|
作者：
Li, Qiang [1 ,2 ]
Yang, Zhihuan [1 ,2 ]
Fang, Kuo [1 ,2 ]
Wei, Shuning [1 ,2 ]
Sun, Jiali [1 ,2 ]
Liu, Wei [1 ,2 ]
Chen, Xiaojuan [1 ,2 ]
Huang, Wenyang [1 ,2 ]
Zhang, Guangji [1 ,2 ]
Shi, Yin [1 ,2 ]
Liu, Yuntao [1 ,2 ]
Gong, Xiaoyuan [1 ,2 ]
Liu, Fang [1 ,2 ]
Zhou, Xueli [1 ,2 ]
Wang, Jianxiang [1 ,2 ]
Wang, Ying [1 ,2 ,3 ,4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin Key Lab Cell Therapy Blood Dis, State Key Lab Expt Hematol,Natl Clin Res Ctr Blood, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China
来源：
BLOOD SCIENCE | 2023年 / 5卷 / 01期
关键词：
D O I：
10.1097/BS9.0000000000000137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：62 / 65
页数：4
相关论文
共 50 条
  • [1] Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients
    Wang, Ying
    Cao, Jiang
    Yan Zhiling
    Qiao, Jianlin
    Li, Deipeng
    Li, Zhenyu
    Xu, Kailin
    BLOOD, 2019, 134
  • [2] Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy
    Tang, Kevin
    Khwaja, Raamis
    Feng, Lei
    Strati, Paolo
    Steiner, Raphael E.
    Nair, Ranjit
    Flowers, Christopher R.
    Saini, Neeraj
    Ramdial, Jeremy L.
    Srour, Samer A.
    Champlin, Richard E.
    Rondon, Gabriela
    Torres, Janet
    Kebriaei, Partow
    Nastoupil, Loretta J.
    Mistry, Haleigh
    Shpall, Elizabeth J.
    Nieto, Yago
    Westin, Jason
    Neelapu, Sattva S.
    Ahmed, Sairah
    BLOOD, 2022, 140 : 4684 - 4685
  • [3] Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
    Lihong An
    Yuehui Lin
    Biping Deng
    Zhichao Yin
    Defeng Zhao
    Zhuojun Ling
    Tong Wu
    Yongqiang Zhao
    Alex H. Chang
    Chunrong Tong
    Shuangyou Liu
    BMC Cancer, 22
  • [4] Toxicities of CD19 CAR-T cell immunotherapy
    Hirayama, Alexandre V.
    Turtle, Cameron J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S42 - S49
  • [5] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
    Li, Xin
    Liu, Mei-Jing
    Mou, Nan
    Yang, Zhen-Xing
    Wang, Jia
    Mu, Juan
    Zhu, Hai-Bo
    Deng, Qi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [6] CD19 CAR-T Cell Therapy: High Efficacy in Autoimmune Diseases
    Brudermanns, Britta
    TRANSFUSIONSMEDIZIN, 2024, 14 (03) : 126 - 126
  • [7] CD19 CAR-T therapy and sepsis: dancing with the devil
    Budde, Lihua E.
    Zaia, John A.
    BLOOD, 2018, 131 (01) : 7 - 8
  • [8] Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
    Wang, Yu
    Xue, Yu-juan
    Zuo, Ying-xi
    Jia, Yue-ping
    Lu, Ai-dong
    Zeng, Hui-min
    Zhang, Le-ping
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [9] Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma
    Gong, Inna Y.
    Tran, Daisy
    Saibil, Samuel
    Laister, Rob C.
    Kuruvilla, John
    HEMASPHERE, 2024, 8 (08):
  • [10] CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?
    Rangel-Pelaez, Carlos
    Martinez-Gutierrez, Laura
    Tristan-Manzano, Maria
    Callejas, Jose Luis
    Ortego-Centeno, Norberto
    Martin, Francisco
    Martin, Javier
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345